Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model

Abstract : Camptothecin (CPT), a plant alkaloid, is a potent anticancer drug in cell culture studies but it is clinically inactive due to rapid hydrolysis under physiological conditions. The drug exists in two forms depending on the pH value, an active lactone form at pH below 5 and an inactive carboxylate form at basic pH and this is a reversible reaction. In this study, nanoparticulate delivery systems were developed with either amphiphilic cyclodextrins, poly(lactide-co-glycolide) or poly-ɛ-caprolactone in order to maintain the active lactone form and prevent the drug from hydrolysis. All nanoparticles were prepared with nanoprecipitation technique. Mean particle sizes were 130–280 nm and surface charges were negative. The encapsulation efficiency was significantly higher for amphiphilic cyclodextrin nanoparticles when compared to polymeric nanoparticles. Nanoparticle formulations based on cyclodextrins showed a controlled release profile extended up to 12 days. 6-O-Capro-β-cyclodextrin (1.44 μg/60 μL CPT) and concentrated 6-O-Capro-β-cyclodextrin (2.88 μg/60 μL CPT) nanoparticles significantly modified the growth or lethality of the 9L gliomas, since the median survival time was 26 days for the untreated group and between 27 and 33 days for amphiphilic cyclodextrin nanoparticle groups. These results indicate that, CPT-loaded amphiphilic cyclodextrin nanoparticles may provide a promising carrier system for the effective delivery of CPT in comparison to polymeric analogues.
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-01865053
Contributor : Martin Soucé <>
Submitted on : Thursday, August 30, 2018 - 5:07:48 PM
Last modification on : Tuesday, May 7, 2019 - 6:30:07 PM

Identifiers

Collections

Citation

Yasemin Çırpanlı, Emilie Allard, Catherine Passirani, Erem Bilensoy, Laurent Lemaire, et al.. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. International Journal of Pharmaceutics, Elsevier, 2011, 403 (1-2), pp.201 - 206. ⟨10.1016/j.ijpharm.2010.10.015⟩. ⟨hal-01865053⟩

Share

Metrics

Record views

51